19 January 2022 - - Canada-based CB1 blockade specialist Inversago Pharma Inc has completed the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder complications, the company said.

Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation, and the company will actively pursue the advancement of INV-202 into later-stage clinical trials.

With encouraging Phase 1 results and supportive preclinical package, Inversago is looking forward to launching Phase 2 clinical development for INV-202.

The CB1 receptor biology and its therapeutic profile are well documented, both clinically and pre-clinically.

In the early 2000s, several major pharmaceutical companies invested massively in this biology, demonstrating the prolific therapeutic benefits a CB1 blockade could provide to patients afflicted with the metabolic syndrome and its complications.

Peripherally-acting CB1 blockers, such as Inversago's first-in-class INV-202, have the potential to provide the same clinical benefits without the previous class-associated psychiatric effects linked to brain target engagement.

Development of a safe and potent peripheral CB1 blockade represents an opportunity to address a significant number of unmet medical needs affecting a growing number of patients globally.

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists.

Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy, Non-Alcoholic Steatohepatitis, complications from obesity, Hypertriglyceridemia, Type 1 Diabetes and Prader-Willi Syndrome, as well as fibrotic indications like Progressive Fibrosis Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis.